Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc (GSK) Shareholders
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
Levi & Korsinsky Notifies Shareholders of GSK plc (GSK) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
The Boston Globe4d
GSK to grow Massachusetts work force with move from Maryland
Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...
Seeking Alpha9d
GSK outlines 2025 growth driven by specialty medicines and new product launches
CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...
Insider Monkey8d
Why GSK plc (GSK) Went Up on Wednesday
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...
Insider Monkey9d
Why GSK Stock Is Surging Today
GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...
Reuters9d
GSK, gold miners shares push Britain's FTSE 100 higher
Feb 5 (Reuters) - UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold miners, while investors turned their focus to the Bank ...
pharmaphorum2d
GSK says $2.2bn settlement resolves most Zantac litigation
GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...
The Motley Fool UK7d
Down 15% and with a P/E below 9! Is the GSK share price still in deep value territory?
Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...
The Motley Fool UK23d
Anywhere under £45.27, GSK’s share price looks cheap to me
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...
pharmaphorum4d
GSK builds neuro, cancer pipeline with trio of deals
GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...